Marina N. Vukolova1
Laura Y. Yen2,3
Margarita I. Khmyz4
Alexander I. Sobolevsky2
Maria V. Yelshanskaya2*- 1Department of Pathophysiology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
- 2Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, United States
- 3Cellular and Molecular Physiology and Biophysics Graduate Program, Columbia University, New York, NY, United States
- 4N. V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Ionotropic glutamate receptors (iGluRs) mediate the majority of excitatory neurotransmission and are implicated in various neurological disorders. In this review, we discuss the role of the two fastest iGluRs subtypes, namely, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors, in the pathogenesis and treatment of Parkinson’s disease, epilepsy, and amyotrophic lateral sclerosis. Although both AMPA and kainate receptors represent promising therapeutic targets for the treatment of these diseases, many of their antagonists show adverse side effects. Further studies of factors affecting the selective subunit expression and trafficking of AMPA and kainate receptors, and a reasonable approach to their regulation by the recently identified novel compounds remain promising directions for pharmacological research.
1 Introduction
The chemical messenger glutamate mediates most excitatory neurotransmission in the mammalian central nervous system (CNS). Although the concentration of glutamate is strictly regulated in physiological conditions, its elevated levels in the synaptic cleft are the principal cause of neuronal death upon stroke and traumatic brain injury, as well as in neurodegenerative conditions (Roisen et al., 1982; Buchan et al., 1993; Couratier et al., 1993). Exposure of neuronal culture to excessive concentrations of glutamate results in rapid cell death (Choi et al., 1988; Olney, 1994) that can be prevented by blocking ionotropic glutamate receptors (iGluRs). iGluRs are cation-permeable glutamate-gated ion channels located predominantly in postsynaptic neuronal membranes (Figure 1). They play a key role in synaptic transmission in the CNS and are involved in synaptic plasticity and processes underlying learning and memory (Lynch, 2006). It is, therefore, not surprising that their dysregulation is associated with numerous pathophysiological conditions (Liu and Zukin, 2007; Traynelis et al., 2010; Paoletti et al., 2013; Parsons and Raymond, 2014; Hansen et al., 2021).
FIGURE 1. Glutamatergic synapse. Presynaptic and postsynaptic neuronal terminals are shown at the top and bottom in the center (yellow), respectively, and glial cells on the left and right (light green). Neurotransmitter glutamate released from the presynaptic terminus is illustrated by bright green circles. AMPA, NMDA, and kainate iGluRs in the postsynaptic membrane and glutamate transporters (EAAT1/2) in glial cells are illustrated by the corresponding molecular models in surface representation. Auxiliary subunits, TARP and CNIH, of the AMPA receptor are represented in dark green and purple, respectively, and Neto of the kainate receptor is represented in dark blue. The principal subunits of iGluRs are represented in light blue and beige, and glutamate transporters are represented in light blue, beige, and light green.
iGluRs are divided into four functional classes: 1) α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (GluA1-4 subunits), 2) kainate receptors (GluK1-5 subunits), 3) N-methyl-d-aspartate (NMDA) receptors (GluN1, GluN2A-D, and GluN3A-B subunits), and 4) GluD receptors, also known as δ receptors (GluD1 and GluD2 subunits). iGluRs were originally named based on their specific activators (Figure 2). AMPA and kainate receptors coassemble with different auxiliary subunits, such as the transmembrane AMPA receptor regulatory proteins (TARPs), cysteine-knot AMPA receptor modulating proteins (CKAMPs), neuropilin- and tolloid-like (Neto) proteins, and KRIP6 (a protein from the BTB/Kelch family) that display differential distribution throughout CNS and cause changes in receptor function and sensitivity to modulators (Figure 1) (Laezza et al., 2007; Gardinier et al., 2016; Kato et al., 2016; Maher et al., 2016; Twomey et al., 2019; Yu et al., 2020; Cull-Candy and Farrant, 2021; Hansen et al., 2021; Yelshanskaya and Sobolevsky, 2022).
FIGURE 2. Chemical structures of iGluR agonists. Chemical structures of neurotransmitter glutamate and selective agonists AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), kainate, and NMDA (N-methyl-d-aspartate).
It is generally accepted that neurodegeneration correlates negatively with synaptic plasticity, which is driven by iGluR function. Since the role of iGluRs in neurodegeneration is a very broad topic, we will only discuss the mechanisms of glutamatergic system dysregulation in the neurogenerative conditions of Parkinson’s disease (PD), epilepsy, and amyotrophic lateral sclerosis (ALS), particularly focusing on non-NMDA receptors, as this topic aligns most with the interests of the authors of this review. We try to be cautious in not oversimplifying the role of iGluRs as they represent a fraction of the larger dynamic ensemble of neuronal receptors involved in synaptic plasticity, which are continuously regulated by new protein biogenesis and trafficking between synaptic and extrasynaptic pools.
2 Parkinson’s disease
PD is the second most common progressive neurodegenerative disorder after Alzheimer’s disease. PD affects 1%–3% of individuals age 65 years or older (Dorsey et al., 2018), and in 3%–5% of cases, individuals can display symptoms previously, before the age of 40 (Golbe, 1991). The estimated number of people with PD in 1990 was 2.5 million, which has more than double and reached 6.2 million by 2015 and is expected to double again and reach 12.9 million by 2040 (Elbaz et al., 2016; Dorsey and Bloem, 2018). PD has been known to mankind since ancient times. In the Indian medical system of Ayurveda (5000 BC), it was called kampavata (“kampa” means tremor in Sanskrit). PD symptoms were also described in the Chinese medical text “Nei-Jing” (500 BC). In Western medicine, the disease was named after Doctor James Parkinson, whose “Essay on the Shaking Palsy” (1817) has long been considered the foundational text about PD (Hurwitz, 2014; Maiti et al., 2017). PD is associated with substantial disability and negative impact on the quality of life, causing characteristic motor symptoms of tremor, bradykinesia, and postural instability (Dorsey et al., 2007). These symptoms are coupled to the loss or degeneration of dopaminergic (dopamine-producing) neurons and development of Lewy Bodies (a pathologic hallmark) in the substantia nigra region of the brain and their axonal projections to the striatum (Maiti et al., 2017). The loss of neurons is followed by the death of astrocytes, which then increases the amount and activation of microglia in the substantia nigra pars compacta (SNpc) (Jankovic, 2008). Clinical symptoms do not appear immediately; they became apparent at the point when approximately half of the cells are destroyed and the disease has already progressed to an advanced stage (Cheng et al., 2011).
Although the causes and driving forces of PD are not well understood, several disease risk factors have been linked to the degeneration of the dopaminergic neurons, including genetics, obesity, and neuroinflammation caused by various environment factors (i.e., exposure to industrial chemicals, pesticides like rotenone, herbicide paraquat, and heavy metals), gut health (Tanner et al., 2011; Bjorklund et al., 2018; Fan et al., 2020; De Miranda et al., 2022), or a combination of them. Thus, recent experiments on mice suggested a synergy between the diet (lectins ingestion), gut health, and environmental toxins in the development of PD (Anselmi et al., 2018).
Currently, there is no cure for PD; the main treatment is symptomatic, and pharmacological interventions have various limitations and side effects. The development of effective preventive or protective therapies is limited by our knowledge of the causes and mechanisms by which neurons die in PD. Which components of neurotransmission that are known to be involved in the pathogenesis of PD play a primary or secondary role in neurodegeneration is not yet well understood because imbalances in the dopamine-releasing system cause further disturbances and imbalances of other components, i.e., acetylcholine/dopamine/glutamate neurotransmission. Although glutamatergic signaling increases and stimulates the release of dopamine through surviving dopaminergic neurons in the SNpc as a compensatory mechanism, increasing glutamate concentrations and excessive activation of glutamate receptors could be a “critical strike” to dopaminergic neurons in PD patients as well (Wang et al., 2020). The approved PD treatments include the use of dopamine receptor agonists (for example, L-DOPA), dopamimetic drugs to relieve the symptoms of impaired motor function (Lutsenko et al., 2003), and deep brain stimulation techniques (Malek, 2019). Although these forms of treatment may partially ameliorate the motor dysfunctions of PD patients, they do not slow the disease progression. Moreover, prolonged therapy frequently leads to the development of motor complications, known as L-DOPA-induced dyskinesia (LID), and dementia. In turn, motor dysfunction is linked to impaired AMPA receptor plasticity (Jurado, 2017; Zhang et al., 2019c; Zhang and Bramham, 2020). Indeed, compared to healthy individuals, synapses of PD patients with motor disturbances accumulate excessive glutamate (Mironova et al., 2018). It is known that elevated oxidative stress causes mutations in glutamate transporters and thus leads to elevated glutamate concentrations in the synaptic cleft (Hoye et al., 2008). The resulting failure to quickly clear synaptic glutamate triggers repetitive action potentials, an increase in calcium influx, and endoplasmic reticulum (ER) and mitochondrial stress due to the overwhelmed ability to calcium storage (Becker et al., 2017). In addition, the upregulation of AMPA receptors in the lateral putamen was observed in advanced PD patients experiencing LID when compared to patients without motor complications (Calon et al., 2003). Accordingly, there is an enormous need to design therapeutics to stop the progression of PD (Zhang and Bramham, 2020; O'Neill et al., 2004; Hughes et al., 1992).
Early detection of PD is crucial for effective neurodegenerative disease interventions. Correspondingly, many researchers focus on identifying genetic factors that increase the risk of disease. Mutations in at least 20 genes have been recognized as causes of familial parkinsonism, each providing a snapshot into the molecular basis of neurodegeneration. Over 90 genetic risk loci for the more common sporadic form of PD have already been identified (Blauwendraat et al., 2020). Although it is more challenging to unravel the precise biological processes disrupted in these genetic variants, the disease-associated genes begin to coalesce into common pathways, including the dysregulation of mitochondrial homeostasis, impaired cell death machinery, inflammatory signaling, intracellular trafficking, and endosomal–lysosomal dysfunction (Tolosa et al., 2021). Genetic predisposition for the early onset of PD was determined for patients with mutations in one of the dominant genes, namely, SNCA, LRRK2, GBA, and VPS35 or recessive genes, namely, Parkin, Pink1, and DJ1 (Post et al., 2020).
Effective strategies for the treatment of PD include normalizing glutamate homeostasis, reducing oxidative stress, and attenuating glial activation (Martin-Moreno et al., 2011; Fernandez-Ruiz et al., 2013; Bhunia et al., 2022). During PD, the mitochondrial Ca2+-buffering system in substantia nigra neurons was shown to be impaired and led to Ca2+-induced excitotoxicity (Hoye et al., 2008; Hurley et al., 2013). One of the strategies in the treatment of PD is limiting the excessive influx of Ca2+ into neurons, including the direct blocking of iGluRs (O'Neill and Witkin, 2007; Jayakar and Dikshit, 2004; Calabrese et al., 2017). In primates, a decrease in LID was observed due to the NMDA receptor channel block (Zuddas et al., 1992; Papa and Chase, 1996). Although NMDA receptor antagonists showed a positive effect against LID both in mice and primates, clinical trials have not yet achieved the desired effects in humans (Duty, 2012). In contrast to NMDA receptors, which are usually inactive at the resting membrane potential due to the channel block by Mg2+ (Mayer et al., 1984; Nowak et al., 1984; Sobolevsky and Yelshansky, 2000), AMPA and kainate receptors are not blocked by extracellular cations and some of them (depending on subunit composition) allow Ca2+ entry into the cell upon activation. AMPA and kainate receptors are typically expressed as heterotetramers, and those assemblies that contain edited GluA2 (for AMPA receptors) or GluK1/2 (for kainate receptors) subunits are calcium-impermeable, while other combinations are calcium-permeable. Due to their high permeability to Ca2+ (and as well to Zn2+) ions, the latter becomes the important target for pharmaceutical intervention (Hansen et al., 2021) (Tables 1, 2). The antagonists of calcium-permeable AMPA receptors were shown to slow the development of LID and reduce the progression of dyskinesia (Kobylecki et al., 2013). It was also shown that the increase in permeability of the substantia nigra neuronal membranes to extracellular zinc leads to the death of nigrostriatal dopaminergic neurons (Tamano et al., 2018). In vivo experiments on rats showed that the injection of the agonist AMPA into the area of spiny projection neurons caused a rapid increase in the intracellular Zn2+ ions and loss of nigrostriatal dopaminergic neurons weeks later. This increase was blocked by the coinjection of intracellular Zn2+ chelators ZnAF-2DA and TPEN, suggesting that the AMPA-induced movement disorder is also a result of intracellular Zn2+ dysregulation (Tamano et al., 2018). Therefore, the regulation of Ca2+- and Zn2+-permeable GluR2-lacking AMPA receptors appears to be particularly important for the treatment of PD.
TABLE 1. AMPA and Kainate receptor antagonists in the treatment of patients with Parkinson’s disease, Epilepsy, ALS.
TABLE 2. The role of AMPA and Kainate receptor antagonists in model animals of Parkinson’s disease, Epilepsy, ALS.
In the PD model of mice lacking 6-hydroxy dopamine (6-OHDA), treated with neurotoxin 6-hydroxydopamine (6-OHDA), which causes the destruction of nigrostriatal dopaminergic neurons (Simola et al., 2007), it was shown that the L-DOPA treatment caused hyperactivity of AMPA receptors. This hyperactivity was possibly due to the alternative splicing of GluA2 or serine phosphorylation of GluA1, which are known to induce a broad range of changes in the AMPA receptor function (Kobylecki et al., 2010; Silverdale et al., 2010). These findings reinforce the role of Ca2+-permeable AMPA receptors in LID and emphasize their potential to serve as therapeutic targets in treating PD-related dyskinesia.
Despite extensive efforts in the development of AMPA receptor antagonists, they alone have not been shown effective in the animal models of PD. For instance, while the high-affinity AMPA receptor antagonist quinoxalinedione NBQX (Figure 3) was found to protect neurons from damage (Ossowska, 1994; Jayakar and Dikshit, 2004), low solubility at physiological pH combined with fast renal excretion caused its crystallization in the kidneys at therapeutic doses (Klockgether et al., 1991; Stauch Slusher et al., 1995; Catarzi et al., 2007). However, when NBQX was used in combination with the inhibitors of dopamine and γ-aminobutyric acid (GABA) receptors, the dyskinesia symptoms improved. Indeed, the synergistic effects of buprenorphine hydrochloride (Hospira), 6-OHDA hydrobromide, and methyl ester L-DOPA hydrochloride confirmed the involvement of dopamine, GABA, and glutamate in the development of dyskinesia (Lindenbach et al., 2016), highlighting the complexity of this multisystem disorder. Similarly, the application of the channel blocker 1-naphthyl acetyl spermine trihydrochloride (NASPM), a synthetic analog of Joro spider toxin (Figure 3), which selectively blocks the Ca2+-permeable AMPA/kainate receptors, to the lateral habenula region had an antidepressant effect in mice with injured substantia nigra (Zhang et al., 2019b). This antidepressant effect was also accompanied with an increase in concentrations of dopamine and serotonin in the medial prefrontal cortex. It appears that future development of more potent and more soluble AMPA receptor blockers shows potential to create an effective treatment of PD. This is in stark contrast to AMPA receptor antagonists, which, at high therapeutic doses along with the positive effect on dyskinesia, also produce CNS depression with negative effects on neuronal plasticity.
FIGURE 3. Sites of AMPA receptor pharmacological regulation. (A) Structure of the GluA2 AMPA receptor (PDB ID: 6DM1) in ribbon representation, viewed parallel to the membrane, with A and C subunits represented in light blue, and B and D subunits represented in beige, and the layers of the amino-terminal domain (ATD), the ligand-binding domain (LBD), and the transmembrane domain (TMD) labeled. Small-molecule regulators are shown in sticks (green). (B) Expanded view of the LBD dimer, with the LBD clamshell binding site of agonists like glutamate and competitive antagonists like NBQX, and the LBD interface binding site of positive allosteric modulators (PAMs) like cyclothiazide (CTZ) being indicated. (C) Expanded view of the TMD, with the binding sites of negative allosteric modulators (NAMs) perampanel (PMP; PDB ID: 5L1F) and trans-4-butylcyclohexane carboxylic acid (4BCCA, PDB ID: 6XSR), as well as ion channel blockers like 1-naphthyl acetyl spermine (NASPM; PDB ID: 6DM1) being indicated. Only two subunits (A,C) are shown, with the front and back subunits (B,D) removed for clarity.
Positive allosteric modulators (PAMs), including nootropic pyrrolidone compounds like aniracetam, oxiracetam, and piracetam, and benzothiazoles like cyclothiazide and diazoxide (Figure 3), which slow deactivation and reduce desensitization of both Ca2+-permeable and Ca2+-impermeable AMPA receptors, are known to have neuroprotective and neurotrophic effects, helping in disorders characterized by a decline in cognitive functions, such as PD (Partin, 2015). PD is defined as a movement disorder, but it is also characterized by a variety non-motor symptoms (NMS) in virtually all patients, including hyposmia, constipation, urinary dysfunction, orthostatic hypotension, memory loss, depression, pain, and sleep disturbances (Tolosa et al., 2021). Several AMPA receptor PAMs are known to improve neuronal plasticity. Biarylpropyl sulfonamide ligands, namely, LY404187 and LY503430, protected the substantia nigra from damage and strengthened synaptic transmission. LY503430 demonstrated a neuroprotective effect in mice with PD (Murray et al., 2003). Low concentrations of this compound selectively increased the glutamate-dependent flow of calcium ions into the cells via subunits GluA1, GluA3, or GluA4, containing AMPA receptors. The neurotrophic effect of LY503430 was in part due to the stimulation of neurotrophic factors BDNF and GAP-4316 production (Zhang et al., 2019a; O’Neill and Witkin, 2007; O’Neill et al., 2005; Murray et al., 2003). The disadvantage of PAMs is that only a small number of them can penetrate the blood–brain barrier.
Alternative pharmacological agents include phytocannabidiol (CBD), an active compound of the Cannabis sativa plant (marijuana), which showed neuroprotective effects in mouse models of several neurodegenerative diseases, including PD (Hampson et al., 1998; Hampson et al., 2000; Lastres-Becker et al., 2005; Garcia et al., 2011; Ruiz-Valdepenas et al., 2011; Pacher et al., 2020). The beneficial effects of CBD observed in the preclinical models of multiple sclerosis (Elliott et al., 2018), PD, and AD can be attributed to the attenuated oxidative/nitrative stress, excitotoxicity, and microglial activation. CBD also significantly reduced AMPA receptor-mediated excitatory postsynaptic currents (EPSCs) and the amplitude and frequency of miniature EPSCs (mEPSCs) in hippocampal neurons, likely affecting the progression of neurodegenerative disorders. Treatment with CBD did not improve motor function or general symptoms in the clinical studies of PD patients but showed improvement in their quality of life and sleep, likely due to a psychotic effect (Peres et al., 2018). Furthermore, CBD was shown to inhibit currents through recombinant GluA1 receptors with an IC50 value of 22.5 µM and significantly accelerated the deactivation of AMPA receptors composed of GluA1 and GluA2 subunits (Patra et al., 2019). Interestingly, CBD slowed recovery from desensitization for Ca2+-permeable GluA1 but not Ca2+-impermeable GluA2 receptors. These effects of CBD on receptor kinetics were even more prominent when AMPA receptors were coexpressed with the auxiliary subunit TARP γ8, which is highly expressed in the hippocampus. It is known that hippocampal damage is a common feature among neurodegenerative dementias (Moodley and Chan, 2014). The inhibitory effect on AMPA receptors depended on the CBD interaction with the N-terminal domain (NTD) of GluA1/GluA2 and was completely eliminated by NTD deletion (Yu et al., 2020).
Another compound found in the C. sativa plant, Tetrahydrocannabinol (THC), has been shown to reduce NMDA, AMPA, and kainate receptor-mediated neurotoxicity (Hampson et al., 2000). An endogenous cannabinoid receptor agonist with similar pharmacological effects as THC is anandamide (AEA, the major psychoactive component of marijuana) that directly inhibits currents through homomeric GluA1 and GluA3 receptors at rather high concentrations, with IC50 values of 161 and 143 μM, respectively, and heteromeric GluA1/3 and GluA2/3 receptors, with the similar IC50 values of 148 and 241 μM, respectively (Akinshola et al., 1999a; Akinshola et al., 1999b). One limitation to using AEA is that it also activates TRPV1 channels, which are highly permeable to Ca2+ and can contribute to neuronal Ca2+ overload (Naziroglu, 2015). Another interesting example is the phytocannabinoid delta 9-tetrahydrocannabivarin (D9-THCV), which undergoes testing in preclinical models of PD (Garcia et al., 2011). There could also be clinical advantages in administering D9-THCV together with CBD as this might lead to symptomatic relief (due to D9-THCV blockade of CB1) and neuroprotection (due to the antioxidant and anti-inflammatory properties of both CBD and D9-THCV). The main difficulty in assessing the drug efficiency is the different time scales of animal and clinical studies. In all animal studies, the effect of drug is monitored shortly after manipulations that induce PD-like symptoms, while in clinical practices, PD is diagnosed 10 years after neurodegeneration has started. Currently, CBD can be considered a preventive agent, without a definitive target, as it affects many enzymes and ion channels, including iGluRs (Peres et al., 2018).
Kainate receptors participate in the regulation of dopaminergic neuron firing frequency, and the expression of the GluK2 subunit is increased in parkinQ311X mouse (a PD model of human parkin-induced toxicity) (Maraschi et al., 2014). Accumulation of GluK2 in the plasma membrane of PD neurons has been shown to be due to slowed GluK2 turnover caused by the loss of parkin protein (ubiquitin E3 ligase that breaks down unnecessary proteins by tagging the damaged and excess proteins with a molecule called ubiquitin), which interacts with the C-terminal tail of GluK2 and is able to ubiquitinate it (Maraschi et al., 2014). Thus, the chronic administration of the kainate receptor antagonist, UBP310, prevented the loss of dopaminergic neurons and increased the survival of the total neuron population in the substantia nigra in the acute MPTP mouse model of PD (Stayte et al., 2020). UBP310 is a 4,000-fold more potent antagonist at kainate vs. AMPA receptors and is ineffective at NMDA and metabotropic glutamate receptors (Dolman et al., 2007; Regoni et al., 2020), making kainate receptors a perspective novel target for neuroprotective therapy.
Microglia and astrocytes were also shown to contribute to neuroinflammation, which can be beneficial short-term by promoting tissue repair and becomes detrimental when sustained (Kwon and Koh, 2020). Various anti-inflammatory treatments, such as using dexamethasone, ibuprofen, amantadine, minocycline, pituitary adenylate cyclase-activating peptide, and vasoactive intestinal peptide, have been shown to prevent the dopaminergic neuron cell death in animal models. Astrocytes also protect motor neurons from excitotoxic damage via the release of an unidentified soluble factor(s) that induces motor neurons to upregulate the glutamate receptor subunit GluA2 (Rosenblum and Trotti, 2017). The incorporation of GluA2 subunits into glutamate receptors reduces their calcium permeability, providing protection from excitotoxicity by decreasing the influx of calcium into neurons.
In summary, the modulation of AMPA and kainate receptors (when thoroughly tuned to achieve specific goals) appears to be an effective strategy in both inhibiting the progression of PD and restoring CNS degeneration (O'Neill et al., 2004).
3 Epilepsy
Epilepsy is a chronic brain disorder characterized by the recurrence of unprovoked seizures caused by abnormal, highly synchronized firing of neurons within a restricted brain region, brain hemisphere, or generalized to the entire brain (Moshe et al., 2015). Seizures occur when clusters of neurons transmit irregular signals. During seizure, many neurons fire (signal) simultaneously at a faster than normal rate, as many as 500 times per second. This surge of excessive and synchronized electrical activity results in involuntary movements, spasms, sensations, emotions, and behaviors, and may cause a loss of consciousness. The word “epilepsy” comes from a Greek word meaning “to seize” or “to attack.” Ancient Greeks believed that the origin of epilepsy is the brain, and it is a divine contribution and a sign of ingenuity. There are several types of epilepsy, and the onset of seizures can be a result of different factors, including prior illnesses, brain injury, abnormal brain development, and, more specifically, autoimmune attack on glutamate receptors (Alexopoulos et al., 2011; Lancaster et al., 2011). However, in many cases, the causes of epilepsy are unknown. For many patients with epilepsy, seizures can be controlled by monotherapy at optimized dosages. Antiepileptic drugs restrain the neuronal activity through various mechanisms, including block of sodium channels or TRPV1, inhibition of excitatory neurotransmission (mainly glutamatergic), or facilitating inhibitory neurotransmission, specifically GABAergic or activated by gamma aminobutyric acid. Their clinical use, however, is limited by side effects. In addition, approximately one-third of patients with refractory epilepsies and other complicated cases, which do not respond to monotherapy, remain untreated (Asth et al., 2021). Therefore, alternative treatment strategies are urgently needed.
Microdialysis and magnetic resonance spectroscopy (MRS) studies showed increased levels of extracellular glutamate in patients with epilepsy (Sarlo and Holton, 2021). Kindling model, an experimental animal model for partial epilepsies, showed both a decrease in GABAergic inhibition and an increase in glutamatergic excitation. These processes are thought to be critically involved in cellular mechanisms underlying the initiation (epileptogenesis) and spread of epileptic seizures that lead to chronic epilepsy (Rogawski et al., 1995). GABA is the major inhibitory neurotransmitter in the brain, which works in balance with the major excitatory neurotransmitter glutamate in healthy individuals. In pharmacological experiments, agonists of iGluRs were shown to be involved in the initiation of seizures and their propagation (Loscher et al., 1999). For example, the infusion of AMPA, kainate, (RS)-2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl) propanoic acid (ATPA), or NMDA elicited involuntary muscle contractions (clonus) and passive partial muscle contractions (tonus) in rodents. Kainate, which acts as a non-desensitizing agonist of AMPA receptors, has been widely used in animal models to induce epilepsy (Kandratavicius et al., 2014). The marine toxin domoic acid, a kainic acid analog from algae or algae-eating fishes, when ingested caused intoxication in humans. Intoxicated patients experienced drug-resistant status epilepticus and developed temporal lobe epilepsy within one year. The consequences of domoic acid intoxication in humans are, therefore, very similar to the kainate-induced status epilepticus in rodents (Ramsdell and Gulland, 2014). These results suggested that the overactivation of AMPA receptors can elicit temporal lobe epilepsy, which is also consistent with a relatively dense expression of AMPA receptors in the hippocampus. There is preclinical and clinical evidence that AMPA receptor antagonists inhibit seizures (Rogawski, 2013; Barker-Haliski and White, 2015). One such AMPA receptor antagonists, perampanel, was approved for the treatment of different forms of epilepsy (Bialer et al., 2010; Hibi et al., 2012; Chen et al., 2014). Perampanel (Figure 3) is a negative allosteric modulator (NAM) that inhibits AMPA receptors with high selectivity by stabilizing their closed state and thereby preventing the opening of the ion channel (Yelshanskaya et al., 2016). It also blocks kainate receptors, but with lower affinity (Yelshanskaya et al., 2016; Taniguchi et al., 2022; Gangwar et al., 2023), and shows little selectivity when acting on different AMPA receptor subtypes (Hanada et al., 2014). In 2012, perampanel was approved as an adjunctive treatment of partial-onset seizures and, in 2015, as a treatment of the primary generalized tonic-clonic seizures in patients 12 years and older (Greenwood and Valdes, 2016). Investigations on the use of perampanel for treatment of other types of seizure disorders are ongoing (Potschka and Trinka, 2019). The antiseizure efficacy of perampanel is dose-dependent, and at high doses, this drug can cause side effects like dizziness, somnolence, headache, fatigue, nausea, and vertigo (Greenwood and Valdes, 2016). The competitive antagonist BGG492 (selurampanel) was advanced into clinical trials by Novartis in 2015 for the treatment of epilepsy. It has also been studied as an acute treatment of migraine and is found to produce some pain relief but with a relatively high rate of side effects. The most common adverse effects are disorders of the nervous system (dizziness, mostly mild to moderate in severity) and gastrointestinal tract (Faught, 2014; Gomez-Mancilla et al., 2014). Similar to quinoxalinediones, BGG492 inhibits both AMPA and kainate receptors.
Dietary strategies can provide seizure control in patients who do not respond to antiseizure drugs (Sills et al., 1986; Martin-McGill et al., 2020; Leitner et al., 2023). There are several types of dietary therapies, all of which are high in fat, to some extent restricted in carbohydrates, and associated with ketosis. Medium-chain triglycerides (MCTs), which are highly abundant in ketogenic diet, including decanoic acid, have long been known to have an acute anticonvulsant effect in animal models (Chang et al., 2016). Interestingly, in the Indian medical system of Ayurveda, epilepsy was treated with ghee, which is about 50% composed of saturated fat (palmitic and oleic acids). Chang et al. (2016) demonstrated that direct inhibition of excitatory neurotransmission by decanoic acid at therapeutically relevant concentrations is a result of non-competitive antagonism of AMPA receptors that likely underlies the antiseizure effects. This inhibitory effect was hypothesized to occur via binding of decanoic acid to sites on the transmembrane M3 helix of the GluA2 AMPA receptor transmembrane domain, distinct from the binding sites of perampanel (Chang et al., 2016). The synergistic effects of perampanel and decanoic acid inhibition of AMPA receptors through different binding sites were demonstrated in an ex vivo model of seizure activity and by inhibiting seizure-induced activity in the human brain slices (Augustin et al., 2018), and may represent a prospective antiepileptic strategy. A novel family of fatty acids, branched derivatives of octanoic acid (OA) related to the MCT ketogenic diet, was also identified as a possible treatment of epilepsy (Chang et al., 2015). An OA derivative with the strongest antiepileptic effects, trans 4-butylcyclohexane carboxylic acid (4-BCCA), was shown to inhibit AMPA receptors with low affinity, acting via transmembrane domain binding sites, distinct from perampanel and ion channel blockers (Figure 3) (Yelshanskaya et al., 2022).
CBD, an active compound of marijuana, significantly prolonged the seizure latency and reduced the severity of thermally induced seizures in a mouse hyperthermia-induced seizure model (Patra et al., 2019), partly due to its effect on AMPA receptors (description in the PD section). CBD has been recently approved in the United States and the European Union as an add-on antiepileptic drug (epidiolex) for the treatment of patients affected by refractory epilepsy, such as Dravet and Lennox–Gastaut syndrome (Pagano et al., 2022), and caused resurgence of interest in pharmacology of cannabinoids in general and phytocannabinoids in particular.
Kainate receptors represent another key class of glutamate receptors that may play an important role in the pathophysiology of epilepsy. It has been shown that these receptors, especially GluK4, are upregulated in the astrocytes of the hippocampus and surrounding cortex during status epilepticus (SE), associated with seizures that last more than 5 min and occur with high frequency (Gibbons et al., 2013; Vargas et al., 2013). Although the functional role of kainate receptors in seizures remains to be determined, selective targeting of astrocytic processes that contribute to glutamate release represents a novel therapeutic strategy for the treatment of epilepsy (Gibbons et al., 2013). More recently, several studies suggested that the presynaptic kainate receptors work cooperatively with the cannabinoid receptors to control the release of glutamate (Marshall et al., 2018) and GABA (Daw et al., 2010; Lourenco et al., 2010; Lourenco et al., 2011; Wyeth et al., 2017).
There is evidence for the direct link between AMPA receptor mutations (GluA2 subtype) and epilepsy, although the corresponding studies are limited, with the majority of identified AMPA receptor mutations linked to cognitive impairment and autism (Salpietro et al., 2019). Genetic changes in the GluA2 subunit were mapped to different parts of the receptor, transmembrane, ligand-binding, and N-terminal domains, suggesting that they produce different effects on the AMPA receptor function, including changes in trafficking (e.g., by increasing the surface expression), rigidifying the receptor’s ligand-binding domains, or altering affinity to glutamate or natural regulators, thus influencing synaptic plasticity.
One notable event that follows seizures in humans and in mouse models of epilepsy is the dramatic increase in expression of the GluA1 flip isoforms. These isoforms not only confer greater glutamate sensitivity than the flop isoforms but, if present in excess, tend to form homomeric Ca2+-permeable AMPA receptors. Either of these features can enhance the excitatory synaptic currents. It has been reported that a splice-modulating oligonucleotide decreased the GluA1 expression and showed antiseizure effects, including reduced postseizure hyperexcitability in neonatal mice (Lykens et al., 2017). Such targeting of specific AMPA subunit isoforms may have a potential to alter the expression of AMPA receptor subtypes involved in the disease states. Likewise, various molecular approaches, including the use of small interfering peptides (Fosgerau and Hoffmann, 2015), have been used successfully to target protein–protein interactions and prevent the endocytosis of AMPA receptors involved in behavioral sensitization models of drug addiction. Small interfering peptides (GluR2-3Y) have also been developed to selectively prevent the endocytosis of AMPA receptors containing GluA2 subunits (Lin et al., 2016). An exciting future possibility is to further develop such approaches and to target specific auxiliary subunits that may be involved in the delivery of Ca2+-permeable AMPA receptors.
4 Amyotrophic lateral sclerosis
ALS, also known as Lou Gehrig’s Disease, is a progressive and fatal neurodegenerative disease, which predominantly affects motor neurons that control voluntary muscle movement, including those located in the spinal cord, brain stem, and motor cortex. Different clinical symptoms of ALS depend on whether the upper or lower motor neurons are damaged (Grad et al., 2017). Neuron injury leads to muscle weakness, progressive paralysis, respiratory failure, and death within 3–5 years after the disease onset (Kawahara and Kwak, 2005). To date, the exact mechanisms of ALS pathogenesis remain unknown. Early biochemical studies revealed increased glutamate levels in the ALS patient’s cerebrospinal fluid (Rothstein et al., 1990; Shaw et al., 1995). The dysfunction of RNA and protein homeostasis, which results in glutamate-mediated excitotoxicity, alongside protein aggregation, mitochondrial dysfunction, and oxidative stress, is also responsible for the ALS-specific neurodegeneration (van den Bos et al., 2019; Zhang and Abdullah, 2013; Taylor et al., 2016). About 10% of ALS cases are inherited within families, almost always as dominant traits and frequently with high penetrance.
The first ALS-associated gene, coding for the cytosolic superoxide dismutase (SOD1), was reported in 1993, with more related genes discovered since (Rosen et al., 1993). SOD1 encodes the ubiquitously expressed cytoplasmic superoxide dismutase, which represents a major cell antioxidant. When misfolded due to mutations, SOD1 leads to the toxic accumulation of aggregated protein, which is a possible toxic contributor to ALS (Taylor et al., 2016). Large protein aggregates in neuronal cells are a hallmark in many neurodegenerative diseases, including PD and AD. However, recent studies showed that the disease-causing mutants of SOD1 are not sufficient to drive the disease acting in motor neurons only and have to act in their glial partners, oligodendrocytes, and astrocytes as well (Yamanaka et al., 2008; Wang et al., 2011). The latter cells represent the final layer of the blood–brain barrier, which supplies nutrients to neurons, buffering ions, and recycling the neurotransmitter glutamate. Astrocytes limit neuronal firing by the rapid recovery of synaptic glutamate and release of factors upregulating GluA2 subunit expression. It was shown that astrocytes from familiar and sporadic ALS patients are toxic to cocultured healthy motor neurons (Haidet-Phillips et al., 2011; Re et al., 2014). Motor neurons seem to exhibit a particular sensitivity to excitotoxicity: they are large in size (long axons) and have high energy requirements, relatively low Ca2+-buffering capacity, and contain molecular chaperones with mitochondrial activity and neurofilament content involved in excitotoxic sensitivity (Menon et al., 2014).
Riluzole, the only drug to prolong, although modestly, the survival of ALS patients, is a potent neuroprotective agent with multimodal effects on neuronal activity. One of the mechanisms of riluzole action, acceleration of glutamate clearance and prevention of excessive excitatory neurotransmitter release from presynaptic terminals, causes an effective reduction in the rate of disease progression. Riluzole was also shown to interact with voltage-dependent sodium channels, highlighting its non-specific action on ligand-gated ion channels (Menon et al., 2014; Dharmadasa and Kiernan, 2018; Fang et al., 2018; Lazarevic et al., 2018; Tarantino et al., 2022).
With a higher sensitivity to excitotoxicity, spinal motor neurons exhibit lower levels of GluA2 subunit expression and consequently higher levels of Ca2+-permeable AMPA receptors than most neuronal subgroups (Kawahara and Kwak, 2005). It was suggested that one possible mechanism of ALS progression is an increased number of Ca2+-permeable AMPA receptors due to an abnormal increase in GluA1 and decrease in GluA2 subunit expressions (Kawahara and Kwak, 2005). In cases of sporadic ALS, there are reduced levels of adenosine deaminase acting on RNA type 2 enzyme (ADAR2) expression, which disrupts the efficient Q/R editing of GluA2 pre-mRNA, also causing increased Ca2+ permeability. The downregulation of ADAR2 is believed to be caused by the transactive response DNA-binding protein TDP-43, a transcriptional regulator, and transport protein that plays an important role in alternative splicing. The behavior of this protein is the most reliable hallmark of the motor neuron pathology during ALS, characterized by abnormally insoluble, mislocalized, hyperphosphorylated, or fragmented TDP-43 (Neumann et al., 2006; Kwong et al., 2008; Chen-Plotkin et al., 2010). Notably, the pathological forms of TDP-43 downregulate ADAR2, leading to a failure in Q/R editing of GluA2 pre-mRNA (Yamashita and Kwak, 2019; Guo and Ma, 2021). The unedited GluA2 AMPA receptor subunit is, therefore, the potential target for the ALS drug development. TDP-43 is the critical component of macromolecular complexes that generate small non-coding RNAs (microRNAs) that function in RNA silencing. The loss of TDP-43 results in the reduced expression of microRNAs in model systems.
In addition, mutant cultural astrocytes induce changes in GluA1 and GluA2 AMPA receptor subunit expression on the surface of motor neurons via the secretion of the tumor necrosis factor alpha (TNF-α) in the astrocyte condition medium, thus leading to their increased vulnerability to excitotoxic damage (Kia et al., 2018). Previous research demonstrated that the application of exogenous TNF-α to neurons instigated a rapid insertion of AMPA receptors into the plasma membrane, in some cases specifically GluA2-lacking Ca2+-permeable AMPA receptors, thus potentiating glutamate-dependent excitotoxic damage (Yin et al., 2012). These findings suggest that targeting the TNF-α-induced AMPA receptor expression might be a novel direction for the design of neuroprotective drugs (Zhao et al., 2010).
Antiepileptic drugs, such as perampanel, improve the ALS phenotype but also cause sedation (Akamatsu et al., 2016). Another AMPA receptor antagonist, talampanel, which was initially found to be beneficial for the ALS patients in phase II clinical trials, failed in phase III clinical trials due to low efficacy. Talampanel has a much shorter half-life in humans (approximately 3–4 h) than perampanel (approximately 105 h) (Pascuzzi et al., 2010). Based on the experiments in mice, two novel chemically modified RNA aptamers, which are easily-soluble in water, showing high potency and selectivity AMPA antagonists, have been recently introduced as a new treatment of ALS, an alternative to traditional, small-molecule compounds (Akamatsu et al., 2022). Since RNA aptamers do not cross the blood–brain barrier, researchers hypothesized that in vivo, the dose of these aptamers can be administered as low as possible to achieve the therapeutic efficacy with minimal or no adverse effects by direct injection into the spinal cord (Akamatsu et al., 2022). Another AMPA/kainate receptor antagonist, NBQX, was evaluated in the mouse model of ALS and found to prevent the kainate-induced motor neuron death and to prolong the animal survival (Van Damme et al., 2003). Clinical trials of other small molecules as potential drugs are ongoing. They include compounds acting on TRP channels, K+ channels, Cl− channels, acetylcholine receptors, Na+ channels, and metabotropic glutamate receptors (Tarantino et al., 2022).
5 Conclusion
Non-NMDA iGluRs, AMPA and kainate receptors, play an important role in the pathogenic mechanisms of epilepsy and neurodegenerative diseases like PD, AD, and ALS. Modulation of their activity, subunit expression, and trafficking using selective antagonists appears to be an effective strategy in alleviating the disease symptoms. However, many of these drugs have negative side effects and/or solubility/bioavailability problems. A reasonable approach to new types of therapeutic interventions targeting the expression and trafficking of non-NMDA receptors, as well as novel types of antagonists (e.g., RNA aptamers) and small molecules that selectively bind and regulate Ca2+-permeable AMPA and kainate receptors, will likely uncover alternative strategies to relieve the burden of both acute and chronic neurodegeneration and ultimately lead to neuroprotection.
Author contributions
MV, LY, and MY wrote the manuscript, which was then edited by MIK and AS. Figures were designed by MY and made by AS. All authors contributed to the article and approved the submitted version.
Funding
AS was supported by NIH (R01 NS083660, R01 NS107253, R01 AR078814, and R01 CA206573).
Acknowledgments
The authors would like to thank Irina Karlina for helping with the literature.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Aizawa, H., Kato, H., Oba, K., Kawahara, T., Okubo, Y., Saito, T., et al. (2022). Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. J. Neurol. 269, 885–896. doi:10.1007/s00415-021-10670-y
Akamatsu, M., Yamashita, T., Hirose, N., Teramoto, S., and Kwak, S. (2016). The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci. Rep. 6, 28649. doi:10.1038/srep28649
Akamatsu, M., Yamashita, T., Teramoto, S., Huang, Z., Lynch, J., Toda, T., et al. (2022). Testing of the therapeutic efficacy and safety of AMPA receptor RNA aptamers in an ALS mouse model. Life Sci. Alliance 5 (4), e202101193. doi:10.26508/lsa.202101193
Akinshola, B. E., Chakrabarti, A., and Onaivi, E. S. (1999a). In-vitro and in-vivo action of cannabinoids. Neurochem. Res. 24, 1233–1240. doi:10.1023/a:1020968922151
Akinshola, B. E., Taylor, R. E., Ogunseitan, A. B., and Onaivi, E. S. (1999b). Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-bromo-cyclic AMP. Naunyn Schmiedeb. Arch. Pharmacol. 360, 242–248. doi:10.1007/s002109900078
Albo, F., Pieri, M., and Zona, C. (2004). Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole. J. Neurosci. Res. 78, 200–207. doi:10.1002/jnr.20244
Alexopoulos, H., Kosmidis, M. L., Dalmau, J., and Dalakas, M. C. (2011). Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies. J. Neurol. 258, 1568–1570. doi:10.1007/s00415-011-5982-4
Anselmi, L., Bove, C., Coleman, F. H., Le, K., Subramanian, M. P., Venkiteswaran, K., et al. (2018). Ingestion of subthreshold doses of environmental toxins induces ascending Parkinsonism in the rat. NPJ Park. Dis. 4, 30. doi:10.1038/s41531-018-0066-0
Asth, L., Iglesias, L. P., De Oliveira, A. C., Moraes, M. F. D., and Moreira, F. A. (2021). Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment. Epilepsy Behav. 121, 106832. doi:10.1016/j.yebeh.2019.106832
Atanasova, T., Savonlehto, T., Kukko-Lukjanov, T. K., Kharybina, Z., Chang, W. C., Lauri, S. E., et al. (2023). Progressive development of synchronous activity in the hippocampal neuronal network is modulated by GluK1 kainate receptors. Neuropharmacology 239, 109671. doi:10.1016/j.neuropharm.2023.109671
Augustin, K., Williams, S., Cunningham, M., Devlin, A. M., Friedrich, M., Jayasekera, A., et al. (2018). Perampanel and decanoic acid show synergistic action against AMPA receptors and seizures. Epilepsia 59, e172–e178. doi:10.1111/epi.14578
Barker-Haliski, M., and White, H. S. (2015). Glutamatergic mechanisms associated with seizures and epilepsy. Cold Spring Harb. Perspect. Med. 5, a022863. doi:10.1101/cshperspect.a022863
Barton, M. E., Peters, S. C., and Shannon, H. E. (2003). Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models. Epilepsy Res. 56, 17–26. doi:10.1016/j.eplepsyres.2003.08.001
Becker, L. A., Huang, B., Bieri, G., Ma, R., Knowles, D. A., Jafar-Nejad, P., et al. (2017). Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367–371. doi:10.1038/nature22038
Bhunia, S., Kolishetti, N., Arias, A. Y., Vashist, A., and Nair, M. (2022). Cannabidiol for neurodegenerative disorders: a comprehensive review. Front. Pharmacol. 13, 989717. doi:10.3389/fphar.2022.989717
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Loiseau, P., and Perucca, E. (2002). Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 51, 31–71. doi:10.1016/s0920-1211(02)00106-7
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., and Tomson, T. (2004). Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 61, 1–48. doi:10.1016/j.eplepsyres.2004.07.010
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., and Tomson, T. (2007). Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. 73, 1–52. doi:10.1016/j.eplepsyres.2006.10.008
Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., and White, H. S. (2010). Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 92, 89–124. doi:10.1016/j.eplepsyres.2010.09.001
Bjorklund, G., Stejskal, V., Urbina, M. A., Dadar, M., Chirumbolo, S., and Mutter, J. (2018). Metals and Parkinson’s disease: mechanisms and biochemical processes. Curr. Med. Chem. 25, 2198–2214. doi:10.2174/0929867325666171129124616
Blauwendraat, C., Nalls, M. A., and Singleton, A. B. (2020). The genetic architecture of Parkinson’s disease. Lancet Neurol. 19, 170–178. doi:10.1016/S1474-4422(19)30287-X
Buchan, A. M., Lesiuk, H., Barnes, K. A., Li, H., Huang, Z. G., Smith, K. E., et al. (1993). AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke 24, I148–I152.
Calabrese, F., Savino, E., Mocaer, E., Bretin, S., Racagni, G., and Riva, M. A. (2017). Upregulation of neurotrophins by S 47445, a novel positive allosteric modulator of AMPA receptors in aged rats. Pharmacol. Res. 121, 59–69. doi:10.1016/j.phrs.2017.04.019
Calon, F., Rajput, A. H., Hornykiewicz, O., Bedard, P. J., and Di Paolo, T. (2003). Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson’s disease. Neurobiol. Dis. 14, 404–416. doi:10.1016/j.nbd.2003.07.003
Canton, T., Bohme, G. A., Boireau, A., Bordier, F., Mignani, S., Jimonet, P., et al. (2001). RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 299, 314–322.
Catarzi, D., Colotta, V., and Varano, F. (2007). Competitive AMPA receptor antagonists. Med. Res. Rev. 27, 239–278. doi:10.1002/med.20084
Chang, P., Augustin, K., Boddum, K., Williams, S., Sun, M., Terschak, J. A., et al. (2016). Seizure control by decanoic acid through direct AMPA receptor inhibition. Brain 139, 431–443. doi:10.1093/brain/awv325
Chang, P., Zuckermann, A. M., Williams, S., Close, A. J., Cano-Jaimez, M., McEvoy, J. P., et al. (2015). Seizure control by derivatives of medium chain fatty acids associated with the ketogenic diet show novel branching-point structure for enhanced potency. J. Pharmacol. Exp. Ther. 352, 43–52. doi:10.1124/jpet.114.218768
Chen, C. Y., Matt, L., Hell, J. W., and Rogawski, M. A. (2014). Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons. PLoS One 9, e108021. doi:10.1371/journal.pone.0108021
Cheng, F., Vivacqua, G., and Yu, S. (2011). The role of alpha-synuclein in neurotransmission and synaptic plasticity. J. Chem. Neuroanat. 42, 242–248. doi:10.1016/j.jchemneu.2010.12.001
Chen-Plotkin, A. S., Lee, V. M., and Trojanowski, J. Q. (2010). TAR DNA-binding protein 43 in neurodegenerative disease. Nat. Rev. Neurol. 6, 211–220. doi:10.1038/nrneurol.2010.18
Choi, D. W., Koh, J. Y., and Peters, S. (1988). Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J. Neurosci. 8, 185–196. doi:10.1523/JNEUROSCI.08-01-00185.1988
Couratier, P., Hugon, J., Sindou, P., Vallat, J. M., and Dumas, M. (1993). Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors. Lancet 341, 265–268. doi:10.1016/0140-6736(93)92615-z
Cull-Candy, S. G., and Farrant, M. (2021). Ca(2+) -permeable AMPA receptors and their auxiliary subunits in synaptic plasticity and disease. J. Physiol. 599, 2655–2671. doi:10.1113/JP279029
Daw, M. I., Pelkey, K. A., Chittajallu, R., and Mcbain, C. J. (2010). Presynaptic kainate receptor activation preserves asynchronous GABA release despite the reduction in synchronous release from hippocampal cholecystokinin interneurons. J. Neurosci. 30, 11202–11209. doi:10.1523/JNEUROSCI.6334-09.2010
De Miranda, B. R., Goldman, S. M., Miller, G. W., Greenamyre, J. T., and Dorsey, E. R. (2022). Preventing Parkinson’s disease: an environmental agenda. J. Park. Dis. 12, 45–68. doi:10.3233/JPD-212922
Dharmadasa, T., and Kiernan, M. C. (2018). Riluzole, disease stage and survival in ALS. Lancet Neurol. 17, 385–386. doi:10.1016/S1474-4422(18)30091-7
Dhir, A., and Chavda, V. (2016). Pre- and post-exposure talampanel (GYKI 53773) against kainic acid seizures in neonatal rats. Pharmacol. Rep. 68, 190–195. doi:10.1016/j.pharep.2015.08.011
Dolman, N. P., More, J. C., Alt, A., Knauss, J. L., Pentikainen, O. T., Glasser, C. R., et al. (2007). Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists. J. Med. Chem. 50, 1558–1570. doi:10.1021/jm061041u
Donevan, S. D., and Rogawski, M. A. (1993). GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 10, 51–59. doi:10.1016/0896-6273(93)90241-i
Dorsey, E. R., and Bloem, B. R. (2018). The Parkinson pandemic-A call to action. JAMA Neurol. 75, 9–10. doi:10.1001/jamaneurol.2017.3299
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., et al. (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68, 384–386. doi:10.1212/01.wnl.0000247740.47667.03
Dorsey, E. R., Sherer, T., Okun, M. S., and Bloem, B. R. (2018). The emerging evidence of the Parkinson pandemic. J. Park. Dis. 8, S3–S8. doi:10.3233/JPD-181474
Duty, S. (2012). Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson’s disease. CNS Drugs 26, 1017–1032. doi:10.1007/s40263-012-0016-z
Eggert, K., Squillacote, D., Barone, P., Dodel, R., Katzenschlager, R., Emre, M., et al. German Competence Network on Parkinson's Disease. (2010). Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov. Disord. 25, 896–905. doi:10.1002/mds.22974
Elbaz, A., Carcaillon, L., Kab, S., and Moisan, F. (2016). Epidemiology of Parkinson’s disease. Rev. Neurol. Paris. 172, 14–26. doi:10.1016/j.neurol.2015.09.012
Elger, C. E., Hong, S. B., Brandt, C., Mancione, L., Han, J., and Strohmaier, C. (2017). BGG492 as an adjunctive treatment in patients with partial-onset seizures: a 12-week, randomized, double-blind, placebo-controlled, phase II dose-titration study with an open-label extension. Epilepsia 58, 1217–1226. doi:10.1111/epi.13771
Elliott, D. M., Singh, N., Nagarkatti, M., and Nagarkatti, P. S. (2018). Cannabidiol attenuates experimental autoimmune encephalomyelitis model of multiple sclerosis through induction of myeloid-derived suppressor cells. Front. Immunol. 9, 1782. doi:10.3389/fimmu.2018.01782
Fan, B., Jabeen, R., Bo, B., Guo, C., Han, M., Zhang, H., et al. (2020). What and how can physical activity prevention function on Parkinson’s disease? Oxid. Med. Cell Longev. 2020, 4293071. doi:10.1155/2020/4293071
Fang, T., Al Khleifat, A., Meurgey, J. H., Jones, A., Leigh, P. N., Bensimon, G., et al. (2018). Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 17, 416–422. doi:10.1016/S1474-4422(18)30054-1
Faught, E. (2014). BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy. Expert Opin. Investig. Drugs 23, 107–113. doi:10.1517/13543784.2014.848854
Fernandez-Ruiz, J., Sagredo, O., Pazos, M. R., Garcia, C., Pertwee, R., Mechoulam, R., et al. (2013). Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br. J. Clin. Pharmacol. 75, 323–333. doi:10.1111/j.1365-2125.2012.04341.x
Fosgerau, K., and Hoffmann, T. (2015). Peptide therapeutics: current status and future directions. Drug Discov. Today 20, 122–128. doi:10.1016/j.drudis.2014.10.003
Gangwar, S. P., Yen, L. Y., Yelshanskaya, M. V., and Sobolevsky, A. I. (2023). Positive and negative allosteric modulation of GluK2 kainate receptors by BPAM344 and antiepileptic perampanel. Cell Rep. 42, 112124. doi:10.1016/j.celrep.2023.112124
Garcia, C., Palomo-Garo, C., Garcia-Arencibia, M., Ramos, J., Pertwee, R., and Fernandez-Ruiz, J. (2011). Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease. Br. J. Pharmacol. 163, 1495–1506. doi:10.1111/j.1476-5381.2011.01278.x
Gardinier, K. M., Gernert, D. L., Porter, W. J., Reel, J. K., Ornstein, P. L., Spinazze, P., et al. (2016). Discovery of the first alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist dependent upon transmembrane AMPA receptor regulatory protein (TARP) gamma-8. J. Med. Chem. 59, 4753–4768. doi:10.1021/acs.jmedchem.6b00125
Gibbons, M. B., Smeal, R. M., Takahashi, D. K., Vargas, J. R., and Wilcox, K. S. (2013). Contributions of astrocytes to epileptogenesis following status epilepticus: opportunities for preventive therapy? Neurochem. Int. 63, 660–669. doi:10.1016/j.neuint.2012.12.008
Golbe, L. I. (1991). Young-onset Parkinson’s disease: a clinical review. Neurology 41, 168–173. doi:10.1212/wnl.41.2_part_1.168
Gomez-Mancilla, B., Brand, R., Jurgens, T. P., Gobel, H., Sommer, C., Straube, A., et al. (2014). Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia 34, 103–113. doi:10.1177/0333102413499648
Grad, L. I., Rouleau, G. A., Ravits, J., and Cashman, N. R. (2017). Clinical spectrum of amyotrophic lateral sclerosis (ALS). Cold Spring Harb. Perspect. Med. 7, a024117. doi:10.1101/cshperspect.a024117
Greenwood, J., and Valdes, J. (2016). Perampanel (fycompa): a review of clinical efficacy and safety in epilepsy. P T 41, 683–698.
Guo, C., and Ma, Y. Y. (2021). Calcium permeable-AMPA receptors and excitotoxicity in neurological disorders. Front. Neural Circuits 15, 711564. doi:10.3389/fncir.2021.711564
Haidet-Phillips, A. M., Hester, M. E., Miranda, C. J., Meyer, K., Braun, L., Frakes, A., et al. (2011). Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 29, 824–828. doi:10.1038/nbt.1957
Hampson, A. J., Grimaldi, M., Axelrod, J., and Wink, D. (1998). Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U.S. A. 95, 8268–8273. doi:10.1073/pnas.95.14.8268
Hampson, A. J., Grimaldi, M., Lolic, M., Wink, D., Rosenthal, R., and Axelrod, J. (2000). Neuroprotective antioxidants from marijuana. Ann. N. Y. Acad. Sci. 899, 274–282. doi:10.1111/j.1749-6632.2000.tb06193.x
Hanada, T., Hashizume, Y., Tokuhara, N., Takenaka, O., Kohmura, N., Ogasawara, A., et al. (2011). Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52, 1331–1340. doi:10.1111/j.1528-1167.2011.03109.x
Hanada, T., Ido, K., and Kosasa, T. (2014). Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model. Pharmacol. Res. Perspect. 2, e00063. doi:10.1002/prp2.63
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., et al. (2021). Structure, function, and pharmacology of glutamate receptor ion channels. Pharmacol. Rev. 73, 1469–1658. doi:10.1124/pharmrev.120.000131
Hibi, S., Ueno, K., Nagato, S., Kawano, K., Ito, K., Norimine, Y., et al. (2012). Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel): a novel, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist. J. Med. Chem. 55, 10584–10600. doi:10.1021/jm301268u
Hotait, M., Ismail, H. H., Saab, G. E., and Salameh, J. S. (2021). An open label pilot study of the safety and tolerability of perampanel in amyotrophic lateral sclerosis. Muscle Nerve 64, 504–508. doi:10.1002/mus.27385
Hoye, A. T., Davoren, J. E., Wipf, P., Fink, M. P., and Kagan, V. E. (2008). Targeting mitochondria. Acc. Chem. Res. 41, 87–97. doi:10.1021/ar700135m
Hughes, A. J., Ben-Shlomo, Y., Daniel, S. E., and Lees, A. J. (1992). What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology 42, 1142–1146. doi:10.1212/wnl.42.6.1142
Hurley, M. J., Brandon, B., Gentleman, S. M., and Dexter, D. T. (2013). Parkinson’s disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 136, 2077–2097. doi:10.1093/brain/awt134
Hurwitz, B. (2014). Urban observation and sentiment in James Parkinson’s essay on the shaking Palsy (1817). Lit. Med. 32, 74–104. doi:10.1353/lm.2014.0002
Jakus, R., Graf, M., Ando, R. D., Balogh, B., Gacsalyi, I., Levay, G., et al. (2004). Effect of two noncompetitive AMPA receptor antagonists GYKI 52466 and GYKI 53405 on vigilance, behavior and spike-wave discharges in a genetic rat model of absence epilepsy. Brain Res. 1008, 236–244. doi:10.1016/j.brainres.2004.01.087
Jankovic, J. (2008). Parkinson’s disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79, 368–376. doi:10.1136/jnnp.2007.131045
Jayakar, S. S., and Dikshit, M. (2004). AMPA receptor regulation mechanisms: future target for safer neuroprotective drugs. Int. J. Neurosci. 114, 695–734. doi:10.1080/00207450490430453
Jurado, S. (2017). AMPA receptor trafficking in natural and pathological aging. Front. Mol. Neurosci. 10, 446. doi:10.3389/fnmol.2017.00446
Kandratavicius, L., Balista, P. A., Lopes-Aguiar, C., Ruggiero, R. N., Umeoka, E. H., Garcia-Cairasco, N., et al. (2014). Animal models of epilepsy: use and limitations. Neuropsychiatr. Dis. Treat. 10, 1693–1705. doi:10.2147/NDT.S50371
Kasteleijn-Nolst Trenite, D., Brandt, C., Mayer, T., Rosenow, F., Schmidt, B., Steinhoff, B. J., et al. (2015). Dose-dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: clear PK/PD relationship. Epilepsia 56, 924–932. doi:10.1111/epi.13008
Kato, A. S., Burris, K. D., Gardinier, K. M., Gernert, D. L., Porter, W. J., Reel, J., et al. (2016). Forebrain-selective AMPA-receptor antagonism guided by TARP gamma-8 as an antiepileptic mechanism. Nat. Med. 22, 1496–1501. doi:10.1038/nm.4221
Kawahara, Y., and Kwak, S. (2005). Excitotoxicity and ALS: what is unique about the AMPA receptors expressed on spinal motor neurons? Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 6, 131–144. doi:10.1080/14660820510037872
Kia, A., Mcavoy, K., Krishnamurthy, K., Trotti, D., and Pasinelli, P. (2018). Astrocytes expressing ALS-linked mutant FUS induce motor neuron death through release of tumor necrosis factor-alpha. Glia 66, 1016–1033. doi:10.1002/glia.23298
Kim, J. E., Choi, H. C., Song, H. K., and Kang, T. C. (2019). Perampanel affects up-stream regulatory signaling pathways of GluA1 phosphorylation in normal and epileptic rats. Front. Cell Neurosci. 13, 80. doi:10.3389/fncel.2019.00080
Klockgether, T., Turski, L., Honore, T., Zhang, Z. M., Gash, D. M., Kurlan, R., et al. (1991). The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 30, 717–723. doi:10.1002/ana.410300513
Kobylecki, C., Cenci, M. A., Crossman, A. R., and Ravenscroft, P. (2010). Calciumpermeable AMPA receptors are involved in the induction and expression of l-DOPAinduced dyskinesia in Parkinson’s disease. J. Neurochem. 114, 499–511. doi:10.1111/j.1471-4159.2010.06776.x
Kobylecki, C., Crossman, A. R., and Ravenscroft, P. (2013). Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson’s disease and L-DOPAinduced dyskinesia. Exp. Neurol. 247, 476–484. doi:10.1016/j.expneurol.2013.01.019
Konitsiotis, S., Blanchet, P. J., Verhagen, L., Lamers, E., and Chase, T. N. (2000). AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54, 1589–1595. doi:10.1212/wnl.54.8.1589
Kwon, H. S., and Koh, S. H. (2020). Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl. Neurodegener. 9, 42. doi:10.1186/s40035-020-00221-2
Kwong, L. K., Uryu, K., Trojanowski, J. Q., and Lee, V. M. (2008). TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. Neurosignals 16, 41–51. doi:10.1159/000109758
Laezza, F., Wilding, T. J., Sequeira, S., Coussen, F., Zhang, X. Z., Hill-Robinson, R., et al. (2007). KRIP6: a novel BTB/kelch protein regulating function of kainate receptors. Mol. Cell Neurosci. 34, 539–550. doi:10.1016/j.mcn.2006.12.003
Lancaster, E., Martinez-Hernandez, E., and Dalmau, J. (2011). Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 77, 179–189. doi:10.1212/WNL.0b013e318224afde
Langan, Y. M., Lucas, R., Jewell, H., Toublanc, N., Schaefer, H., Sander, J. W., et al. (2003). Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia 44, 46–53. doi:10.1046/j.1528-1157.2003.128902.x
Laryushkin, D. P., Maiorov, S. A., Zinchenko, V. P., Mal'tseva, V. N., Gaidin, S. G., and Kosenkov, A. M. (2023). Of the mechanisms of paroxysmal depolarization shifts: generation and maintenance of bicuculline-induced paroxysmal activity in rat hippocampal cell cultures. Int. J. Mol. Sci. 24, 10991. doi:10.3390/ijms241310991
Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., and Fernández-Ruiz, J. (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease. Neurobiol. Dis. 19, 96–107. doi:10.1016/j.nbd.2004.11.009
Lazarevic, V., Yang, Y., Ivanova, D., Fejtova, A., and Svenningsson, P. (2018). Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool. Neuropharmacology 143, 38–48. doi:10.1016/j.neuropharm.2018.09.021
Lees, A., Fahn, S., Eggert, K. M., Jankovic, J., Lang, A., Micheli, F., et al. (2012). Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov. Disord. 27, 284–288. doi:10.1002/mds.23983
Leitner, D. F., Siu, Y., Korman, A., Lin, Z., Kanshin, E., Friedman, D., et al. (2023). Metabolomic, proteomic, and transcriptomic changes in adults with epilepsy on modified Atkins diet. Epilepsia 64, 1046–1060. doi:10.1111/epi.17540
Lim, S. N., Wu, T., Tseng, W. J., Chiang, H. I., Cheng, M. Y., Lin, W. R., et al. (2021). Efficacy and safety of perampanel in refractory and super-refractory status epilepticus: cohort study of 81 patients and literature review. J. Neurol. 268, 3744–3757. doi:10.1007/s00415-021-10506-9
Lin, X. J., Zhang, J. J., and Yu, L. C. (2016). GluR2-3Y inhibits the acquisition and reinstatement of morphine-induced conditioned place preference in rats. Neurosci. Bull. 32, 177–182. doi:10.1007/s12264-016-0018-9
Lindenbach, D., Conti, M. M., Ostock, C. Y., George, J. A., Goldenberg, A. A., Melikhov-Sosin, M., et al. (2016). The role of primary motor cortex (M1) glutamate and GABA signaling in l-DOPA-induced dyskinesia in parkinsonian rats. J. Neurosci. 36, 9873–9887. doi:10.1523/JNEUROSCI.1318-16.2016
Lippman-Bell, J. J., Rakhade, S. N., Klein, P. M., Obeid, M., Jackson, M. C., Joseph, A., et al. (2013). AMPA receptor antagonist NBQX attenuates later-life epileptic seizures and autistic-like social deficits following neonatal seizures. Epilepsia 54, 1922–1932. doi:10.1111/epi.12378
Liu, S. J., and Zukin, R. S. (2007). Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends Neurosci. 30, 126–134. doi:10.1016/j.tins.2007.01.006
Loscher, W., Lehmann, H., Behl, B., Seemann, D., Teschendorf, H. J., Hofmann, H. P., et al. (1999). A new pyrrolyl-quinoxalinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsy. Eur. J. Neurosci. 11, 250–262. doi:10.1046/j.1460-9568.1999.00432.x
Lourenco, J., Cannich, A., Carta, M., Coussen, F., Mulle, C., and Marsicano, G. (2010). Synaptic activation of kainate receptors gates presynaptic CB(1) signaling at GABAergic synapses. Nat. Neurosci. 13, 197–204. doi:10.1038/nn.2481
Lourenco, J., Matias, I., Marsicano, G., and Mulle, C. (2011). Pharmacological activation of kainate receptors drives endocannabinoid mobilization. J. Neurosci. 31, 3243–3248. doi:10.1523/JNEUROSCI.3512-10.2011
Lutsenko, V. K., Vukolova, M. N., Kucheryanu, V. G., and Gudasheva, T. A. (2003). Dipeptide analog of neurotensin active site prevents the development of experimental Parkinson’s syndrome in mice. Bull. Exp. Biol. Med. 136, 352–354. doi:10.1023/b:bebm.0000010949.44563.15
Lykens, N. M., Coughlin, D. J., Reddi, J. M., Lutz, G. J., and Tallent, M. K. (2017). AMPA GluA1-flip targeted oligonucleotide therapy reduces neonatal seizures and hyperexcitability. PLoS One 12, e0171538. doi:10.1371/journal.pone.0171538
Lynch, G. (2006). Glutamate-based therapeutic approaches: ampakines. Curr. Opin. Pharmacol. 6, 82–88. doi:10.1016/j.coph.2005.09.005
Maher, M. P., Wu, N., Ravula, S., Ameriks, M. K., Savall, B. M., Liu, C., et al. (2016). Discovery and characterization of AMPA receptor modulators selective for TARP-γ8. J. Pharmacol. Exp. Ther. 357, 394–414. doi:10.1124/jpet.115.231712
Maiti, P., Manna, J., and Dunbar, G. L. (2017). Current understanding of the molecular mechanisms in Parkinson’s disease: targets for potential treatments. Transl. Neurodegener. 6, 28. doi:10.1186/s40035-017-0099-z
Malek, N. (2019). Deep brain stimulation in Parkinson’s disease. Neurol. India 67, 968–978. doi:10.4103/0028-3886.266268
Mammi, A., Ferlazzo, E., Gasparini, S., Bova, V., Neri, S., Labate, A., et al. (2022). Psychiatric and behavioural side effects associated with perampanel in patients with temporal lobe epilepsy. A real-world experience. Front. Neurol. 13, 839985. doi:10.3389/fneur.2022.839985
Maraschi, A., Ciammola, A., Folci, A., Sassone, F., Ronzitti, G., Cappelletti, G., et al. (2014). Parkin regulates kainate receptors by interacting with the GluK2 subunit. Nat. Commun. 5, 5182. doi:10.1038/ncomms6182
Marin, C., Jimenez, A., Bonastre, M., Vila, M., Agid, Y., Hirsch, E. C., et al. (2001). LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. Synapse 42, 40–47. doi:10.1002/syn.1097
Marshall, J. J., Xu, J., and Contractor, A. (2018). Kainate receptors inhibit glutamate release via mobilization of endocannabinoids in striatal direct pathway spiny projection neurons. J. Neurosci. 38, 3901–3910. doi:10.1523/JNEUROSCI.1788-17.2018
Martin-Mcgill, K. J., Bresnahan, R., Levy, R. G., and Cooper, P. N. (2020). Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst. Rev. 6, CD001903. doi:10.1002/14651858.CD001903.pub5
Martin-Moreno, A. M., Reigada, D., Ramirez, B. G., Mechoulam, R., Innamorato, N., Cuadrado, A., et al. (2011). Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease. Mol. Pharmacol. 79, 964–973. doi:10.1124/mol.111.071290
Mayer, M. L., Westbrook, G. L., and Guthrie, P. B. (1984). Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature 309, 261–263. doi:10.1038/309261a0
Menon, P., Kiernan, M. C., and Vucic, S. (2014). Biomarkers and future targets for development in amyotrophic lateral sclerosis. Curr. Med. Chem. 21, 3535–3550. doi:10.2174/0929867321666140601161148
Mironova, Y. S., Zhukova, I. A., Zhukova, N. G., Alifirova, V. M., Izhboldina, O. P., and Latypova, A. V. (2018). Parkinson’s disease and glutamate excitotoxicity. Zh Nevrol. Psikhiatr Im. S S Korsakova 118, 50–54. doi:10.17116/jnevro201811806250
Moodley, K. K., and Chan, D. (2014). The hippocampus in neurodegenerative disease. Front. Neurol. Neurosci. 34, 95–108. doi:10.1159/000356430
Moshe, S. L., Perucca, E., Ryvlin, P., and Tomson, T. (2015). Epilepsy: new advances. Lancet 385, 884–898. doi:10.1016/S0140-6736(14)60456-6
Murray, T. K., Whalley, K., Robinson, C. S., Ward, M. A., Hicks, C. A., Lodge, D., et al. (2003). LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson’s disease. J. Pharmacol. Exp. Ther. 306, 752–762. doi:10.1124/jpet.103.049445
Naziroglu, M. (2015). TRPV1 channel: a potential drug target for treating epilepsy. Curr. Neuropharmacol. 13, 239–247. doi:10.2174/1570159x13666150216222543
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133. doi:10.1126/science.1134108
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., and Prochiantz, A. (1984). Magnesium gates glutamate-activated channels in mouse central neurones. Nature 307, 462–465. doi:10.1038/307462a0
Olney, J. W. (1994). Excitatory transmitter neurotoxicity. Neurobiol. Aging 15, 259–260. doi:10.1016/0197-4580(94)90127-9
O’Neill, M. J., Bleakman, D., Zimmerman, D. M., and Nisenbaum, E. S. (2004). AMPA receptor potentiators for the treatment of CNS disorders. Curr. Drug Targets CNS Neurol. Disord. 3, 181–194. doi:10.2174/1568007043337508
O’Neill, M. J., Murray, T. K., Clay, M. P., Lindstrom, T., Yang, C. R., and Nisenbaum, E. S. (2005). LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson’s disease. CNS Drug Rev. 11, 77–96. doi:10.1111/j.1527-3458.2005.tb00037.x
O’Neill, M. J., and Witkin, J. M. (2007). AMPA receptor potentiators: application for depression and Parkinson’s disease. Curr. Drug Targets 8, 603–620. doi:10.2174/138945007780618517
Orain, D., Tasdelen, E., Haessig, S., Koller, M., Picard, A., Dubois, C., et al. (2017). Design and synthesis of selurampanel, a novel orally active and competitive AMPA receptor antagonist. Chem. Med. Chem. 12, 197–201. doi:10.1002/cmdc.201600467
Oskarsson, B., Mauricio, E. A., Shah, J. S., Li, Z., and Rogawski, M. A. (2021). Cortical excitability threshold can be increased by the AMPA blocker Perampanel in amyotrophic lateral sclerosis. Muscle Nerve 64, 215–219. doi:10.1002/mus.27328
Ossowska, K. (1994). The role of excitatory amino acids in experimental models of Parkinson’s disease. J. Neural Transm. Park Dis. Dement. Sect. 8, 39–71. doi:10.1007/BF02250917
Pacher, P., Kogan, N. M., and Mechoulam, R. (2020). Beyond THC and endocannabinoids. Annu. Rev. Pharmacol. Toxicol. 60, 637–659. doi:10.1146/annurev-pharmtox-010818-021441
Pagano, C., Navarra, G., Coppola, L., Avilia, G., Bifulco, M., and Laezza, C. (2022). Cannabinoids: therapeutic use in clinical practice. Int. J. Mol. Sci. 23, 3344. doi:10.3390/ijms23063344
Paizs, M., Tortarolo, M., Bendotti, C., Engelhardt, J. I., and Siklos, L. (2011). Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotroph. Lateral. Scler. 12, 340–344. doi:10.3109/17482968.2011.584627
Paoletti, P., Bellone, C., and Zhou, Q. (2013). NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 14, 383–400. doi:10.1038/nrn3504
Papa, S. M., and Chase, T. N. (1996). Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys. Ann. Neurol. 39, 574–578. doi:10.1002/ana.410390505
Parsons, M. P., and Raymond, L. A. (2014). Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 82, 279–293. doi:10.1016/j.neuron.2014.03.030
Partin, K. M. (2015). AMPA receptor potentiators: from drug design to cognitive enhancement. Curr. Opin. Pharmacol. 20, 46–53. doi:10.1016/j.coph.2014.11.002
Pascuzzi, R. M., Shefner, J., Chappell, A. S., Bjerke, J. S., Tamura, R., Chaudhry, V., et al. (2010). A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 11, 266–271. doi:10.3109/17482960903307805
Patai, R., Paizs, M., Tortarolo, M., Bendotti, C., Obal, I., Engelhardt, J. I., et al. (2017). Presymptomatically applied AMPA receptor antagonist prevents calcium increase in vulnerable type of motor axon terminals of mice modeling amyotrophic lateral sclerosis. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 1739–1748. doi:10.1016/j.bbadis.2017.05.016
Patra, P. H., Barker-Haliski, M., White, H. S., Whalley, B. J., Glyn, S., Sandhu, H., et al. (2019). Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models. Epilepsia 60, 303–314. doi:10.1111/epi.14629
Peres, F. F., Lima, A. C., Hallak, J. E. C., Crippa, J. A., Silva, R. H., and Abilio, V. C. (2018). Cannabidiol as a promising strategy to treat and prevent movement disorders? Front. Pharmacol. 9, 482. doi:10.3389/fphar.2018.00482
Perier, C., Marin, C., Bonastre, M., Tolosa, E., and Hirsch, E. C. (2002). AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa. Eur. J. Neurosci. 16, 2236–2240. doi:10.1046/j.1460-9568.2002.02275.x
Pinheiro, P. S., Lanore, F., Veran, J., Artinian, J., Blanchet, C., Crepel, V., et al. (2013). Selective block of postsynaptic kainate receptors reveals their function at hippocampal mossy fiber synapses. Cereb. Cortex. 23, 323–331. doi:10.1093/cercor/bhs022
Pitkänen, A., Mathiesen, C., Rønn, L. C., Møller, A., and Nissinen, J. (2007). Effect of novel AMPA antagonist, NS1209, on status epilepticus. Epilepsy Res. 74, 45–54. doi:10.1016/j.eplepsyres.2006.12.004
Post, B., Van Den Heuvel, L., Van Prooije, T., Van Ruissen, X., Van De Warrenburg, B., and Nonnekes, J. (2020). Young onset Parkinson’s disease: a modern and tailored approach. J. Park. Dis. 10, S29–S36. doi:10.3233/JPD-202135
Potschka, H., and Trinka, E. (2019). Perampanel: does it have broad-spectrum potential? Epilepsia 60, 22–36. doi:10.1111/epi.14456
Ramsdell, J. S., and Gulland, F. M. (2014). Domoic acid epileptic disease. Mar. Drugs 12, 1185–1207. doi:10.3390/md12031185
Rascol, O., Barone, P., Behari, M., Emre, M., Giladi, N., Olanow, C. W., et al. (2012). Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin. Neuropharmacol. 35, 15–20. doi:10.1097/WNF.0b013e318241520b
Re, D. B., Le Verche, V., Yu, C., Amoroso, M. W., Politi, K. A., Phani, S., et al. (2014). Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron 81, 1001–1008. doi:10.1016/j.neuron.2014.01.011
Regoni, M., Cattaneo, S., Mercatelli, D., Novello, S., Passoni, A., Bagnati, R., et al. (2020). Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity. Cell Death Dis. 11, 963. doi:10.1038/s41419-020-03172-8
Rogawski, M. A. (2013). AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol. Scand. Suppl, 9–18. doi:10.1111/ane.12099
Rogawski, M. A., Kurzman, P. S., Yamaguchi, S. I., and Li, H. (2001). Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. Neuropharmacology 40, 28–35. doi:10.1016/s0028-3908(00)00112-x
Rogawski, M. A., Le, D. Q., Uyakul, D., Pannell, L. K., Subramaniam, S., Yamaguchi, S., et al. (1995). Anticonvulsant efficacy of ADCI (5-aminocarbonyl-10,11-dihydro-5Hdibenzo[a,d]cyclohepten-5,10-imine) after acute and chronic dosing in mice. Epilepsia 36, 566–571. doi:10.1111/j.1528-1157.1995.tb02568.x
Roisen, F. J., Bartfeld, H., Donnenfeld, H., and Baxter, J. (1982). Neuron specific in vitro cytotoxicity of sera from patients with amyotrophic lateral sclerosis. Muscle Nerve 5, 48–53. doi:10.1002/mus.880050109
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59–62. doi:10.1038/362059a0
Rosenblum, L. T., and Trotti, D. (2017). EAAT2 and the molecular signature of amyotrophic lateral sclerosis. Adv. Neurobiol. 16, 117–136. doi:10.1007/978-3-319-55769-4_6
Rothstein, J. D., Tsai, G., Kuncl, R. W., Clawson, L., Cornblath, D. R., Drachman, D. B., et al. (1990). Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Neurol. 28, 18–25. doi:10.1002/ana.410280106
Ruel, J., Guitton, M. J., and Puell, J. L. (2002). Negative allosteric modulation of AMPA-preferring receptors by the selective isomer GYKI 53784 (LY303070), a specific non-competitive AMPA antagonist. CNS Drug Rev. 8, 235–254. doi:10.1111/j.1527-3458.2002.tb00227.x
Ruiz-Valdepenas, L., Martinez-Orgado, J. A., Benito, C., Millan, A., Tolon, R. M., and Romero, J. (2011). Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study. J. Neuroinflammation 8, 5. doi:10.1186/1742-2094-8-5
Sabers, A., Wolf, P., Moller, A., Rysgaard, K., and Ben-Menachem, E. (2013). A prospective, randomized, multicentre trial for the treatment of refractory status epilepticus; experiences from evaluating the effect of the novel drug candidate, NS1209. Epilepsy Res. 106, 292–295. doi:10.1016/j.eplepsyres.2013.04.002
Salpietro, V., Dixon, C. L., Guo, H., Bello, O. D., Vandrovcova, J., Efthymiou, S., et al. (2019). AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nat. Commun. 10, 3094. doi:10.1038/s41467-019-10910-w
Sarlo, G. L., and Holton, K. F. (2021). Brain concentrations of glutamate and GABA in human epilepsy: a review. Seizure 91, 213–227. doi:10.1016/j.seizure.2021.06.028
Shaw, P. J., Forrest, V., Ince, P. G., Richardson, J. P., and Wastell, H. J. (1995). CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 4, 209–216. doi:10.1006/neur.1995.0026
Sills, M. A., Forsythe, W. I., Haidukewych, D., Macdonald, A., and Robinson, M. (1986). The medium chain triglyceride diet and intractable epilepsy. Arch. Dis. Child. 61, 1168–1172. doi:10.1136/adc.61.12.1168
Silverdale, M. A., Kobylecki, C., Hallett, P. J., Li, Q., Dunah, A. W., Ravenscroft, P., et al. (2010). Synaptic recruitment of AMPA glutamate receptor subunits in levodopainduced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse 64, 177–180. doi:10.1002/syn.20739
Smolders, I., Bortolotto, Z. A., Clarke, V. R., Warre, R., Khan, G. M., O'Neill, M. J., et al. (2002). Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizures. Nat. Neurosci. 5, 796–804. doi:10.1038/nn880
Sobolevsky, A. I., and Yelshansky, M. V. (2000). The trapping block of NMDA receptor channels in acutely isolated rat hippocampal neurones. J. Physiol. 526, 493–506. doi:10.1111/j.1469-7793.2000.t01-2-00493.x
Stauch Slusher, B., Rissolo, K. C., Anzilotti, K. F., and Jackson, P. F. (1995). Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats. J. Neural Transm. Park Dis. Dement. Sect. 9, 145–149. doi:10.1007/BF02259656
Stayte, S., Laloli, K. J., Rentsch, P., Lowth, A., Li, K. M., Pickford, R., et al. (2020). The kainate receptor antagonist UBP310 but not single deletion of GluK1, GluK2, or GluK3 subunits, inhibits MPTP-induced degeneration in the mouse midbrain. Exp. Neurol. 323, 113062. doi:10.1016/j.expneurol.2019.113062
Steinhoff, B. J., Ben-Menachem, E., Ryvlin, P., Shorvon, S., Kramer, L., Satlin, A., et al. (2013). Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 54, 1481–1489. doi:10.1111/epi.12212
Tamano, H., Morioka, H., Nishio, R., Takeuchi, A., and Takeda, A. (2018). AMPA-induced extracellular Zn2+ influx into nigral dopaminergic neurons causes movement disorder in rats. Neurotoxicology 69, 23–28. doi:10.1016/j.neuro.2018.08.008
Taniguchi, S., Stolz, J. R., and Swanson, G. T. (2022). The antiseizure drug perampanel is a subunit-selective negative allosteric modulator of kainate receptors. J. Neurosci. 42, 5499–5509. doi:10.1523/JNEUROSCI.2397-21.2022
Tanner, C. M., Kamel, F., Ross, G. W., Hoppin, J. A., Goldman, S. M., Korell, M., et al. (2011). Rotenone, paraquat, and Parkinson’s disease. Environ. Health Perspect. 119, 866–872. doi:10.1289/ehp.1002839
Tarantino, N., Canfora, I., Camerino, G. M., and Pierno, S. (2022). Therapeutic targets in amyotrophic lateral sclerosis: focus on ion channels and skeletal muscle. Cells 11, 415. doi:10.3390/cells11030415
Taylor, J. P., Brown, R. H., and Cleveland, D. W. (2016). Decoding ALS: from genes to mechanism. Nature 539, 197–206. doi:10.1038/nature20413
Tolosa, E., Garrido, A., Scholz, S. W., and Poewe, W. (2021). Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 20, 385–397. doi:10.1016/S1474-4422(21)00030-2
Traynelis, S. F., Wollmuth, L. P., Mcbain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., et al. (2010). Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev. 62, 405–496. doi:10.1124/pr.109.002451
Twele, F., Bankstahl, M., Klein, S., Romermann, K., and Loscher, W. (2015). The AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy. Neuropharmacology 95, 234–242. doi:10.1016/j.neuropharm.2015.03.014
Twomey, E. C., Yelshanskaya, M. V., and Sobolevsky, A. I. (2019). Structural and functional insights into transmembrane AMPA receptor regulatory protein complexes. J. Gen. Physiol. 151, 1347–1356. doi:10.1085/jgp.201812264
Ueda, J., Uemura, N., Sawamura, M., Taguchi, T., Ikuno, M., Kaji, S. Y., et al. (2021). Perampanel inhibits α-synuclein transmission in Parkinson's disease models. Mov. Disord. 36, 1554–1564. doi:10.1002/mds.28558
Van Damme, P., Leyssen, M., Callewaert, G., Robberecht, W., and Van Den Bosch, L. (2003). The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci. Lett. 343, 81–84. doi:10.1016/s0304-3940(03)00314-8
Van Den Bos, M. A. J., Geevasinga, N., Higashihara, M., Menon, P., and Vucic, S. (2019). Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques. Int. J. Mol. Sci. 20, 2818. doi:10.3390/ijms20112818
Van Den Bosch, L., Vandenberghe, W., Klaassen, H., Van Houtte, E., and Robberecht, W. (2000). Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons. J. Neurol. Sci. 180, 29–34. doi:10.1016/s0022-510x(00)00414-7
Vargas, J. R., Takahashi, D. K., Thomson, K. E., and Wilcox, K. S. (2013). The expression of kainate receptor subunits in hippocampal astrocytes after experimentally induced status epilepticus. J. Neuropathol. Exp. Neurol. 72, 919–932. doi:10.1097/NEN.0b013e3182a4b266
Wang, J., Wang, F., Mai, D., and Qu, S. (2020). Molecular mechanisms of glutamate toxicity in Parkinson’s disease. Front. Neurosci. 14, 585584. doi:10.3389/fnins.2020.585584
Wang, L., Gutmann, D. H., and Roos, R. P. (2011). Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum. Mol. Genet. 20, 286–293. doi:10.1093/hmg/ddq463
Wyeth, M. S., Pelkey, K. A., Yuan, X., Vargish, G., Johnston, A. D., Hunt, S., et al. (2017). Neto auxiliary subunits regulate interneuron somatodendritic and presynaptic kainate receptors to control network inhibition. Cell Rep. 20, 2156–2168. doi:10.1016/j.celrep.2017.08.017
Yamanaka, K., Chun, S. J., Boillee, S., Fujimori-Tonou, N., Yamashita, H., Gutmann, D. H., et al. (2008). Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 11, 251–253. doi:10.1038/nn2047
Yamashita, T., and Kwak, S. (2019). Cell death cascade and molecular therapy in ADAR2-deficient motor neurons of ALS. Neurosci. Res. 144, 4–13. doi:10.1016/j.neures.2018.06.004
Yelshanskaya, M. V., Singh, A. K., Narangoda, C., Williams, R. S. B., Kurnikova, M. G., and Sobolevsky, A. I. (2022). Structural basis of AMPA receptor inhibition by trans4-butylcyclohexane carboxylic acid. Br. J. Pharmacol. 179, 3628–3644. doi:10.1111/bph.15254
Yelshanskaya, M. V., Singh, A. K., Sampson, J. M., Narangoda, C., Kurnikova, M., and Sobolevsky, A. I. (2016a). Structural bases of noncompetitive inhibition of AMPA-subtype ionotropic glutamate receptors by antiepileptic drugs. Neuron 91, 1305–1315. doi:10.1016/j.neuron.2016.08.012
Yelshanskaya, M. V., and Sobolevsky, A. I. (2022). Structural insights into function of ionotropic glutamate receptors. Biochem. Mosc. Suppl. Ser. A Membr. Cell Biol. 16, 190–206. doi:10.1134/s1990747822040043
Yin, H. Z., Hsu, C. I., Yu, S., Rao, S. D., Sorkin, L. S., and Weiss, J. H. (2012). TNF-alpha triggers rapid membrane insertion of Ca(2+) permeable AMPA receptors into adult motor neurons and enhances their susceptibility to slow excitotoxic injury. Exp. Neurol. 238, 93–102. doi:10.1016/j.expneurol.2012.08.004
Yu, Y., Yang, Z., Jin, B., Qin, X., Zhu, X., Sun, J., et al. (2020). Cannabidiol inhibits febrile seizure by modulating AMPA receptor kinetics through its interaction with the N-terminal domain of GluA1/GluA2. Pharmacol. Res. 161, 105128. doi:10.1016/j.phrs.2020.105128
Zhang, H., and Bramham, C. R. (2020). Bidirectional dysregulation of AMPA receptor-mediated synaptic transmission and plasticity in brain disorders. Front. Synaptic Neurosci. 12, 26. doi:10.3389/fnsyn.2020.00026
Zhang, J., and Abdullah, J. M. (2013). The role of GluA1 in central nervous system disorders. Rev. Neurosci. 24, 499–505. doi:10.1515/revneuro-2013-0021
Zhang, J., Lv, S., Tang, G., Bian, G., Yang, Y., Li, R., et al. (2019a). Activation of calcium-impermeable GluR2-containing AMPA receptors in the lateral habenula produces antidepressant-like effects in a rodent model of Parkinson’s disease. Exp. Neurol. 322, 113058. doi:10.1016/j.expneurol.2019.113058
Zhang, J., Wang, Y., Sun, Y. N., Li, L. B., Zhang, L., Guo, Y., et al. (2019b). Blockade of calcium-permeable AMPA receptors in the lateral habenula produces increased antidepressant-like effects in unilateral 6-hydroxydopamine-lesioned rats compared to sham-lesioned rats. Neuropharmacology 157, 107687. doi:10.1016/j.neuropharm.2019.107687
Zhang, Z., Zhang, S., Fu, P., Zhang, Z., Lin, K., Ko, J. K., et al. (2019c). Roles of glutamate receptors in Parkinson’s disease. Int. J. Mol. Sci. 20, 4391. doi:10.3390/ijms20184391
Zhao, P., Leonoudakis, D., Abood, M. E., and Beattie, E. C. (2010). Cannabinoid receptor activation reduces TNF-alpha-induced surface localization of AMPAR-type glutamate receptors and excitotoxicity. Neuropharmacology 58, 551–558. doi:10.1016/j.neuropharm.2009.07.035
Keywords: glutamate receptors, AMPA, Parkinson’s disease, epilepsy, ALS, kainate receptors, 4-BCCA, antagonist
Citation: Vukolova MN, Yen LY, Khmyz MI, Sobolevsky AI and Yelshanskaya MV (2023) Parkinson’s disease, epilepsy, and amyotrophic lateral sclerosis—emerging role of AMPA and kainate subtypes of ionotropic glutamate receptors. Front. Cell Dev. Biol. 11:1252953. doi: 10.3389/fcell.2023.1252953
Received: 04 July 2023; Accepted: 05 October 2023;
Published: 24 October 2023.
Edited by:
Khaled S. Abd-Elrahman, University of British Columbia, CanadaReviewed by:
Antonio De Iure, IRCCS San Raffaele Roma s.r.l., ItalyXiangping Chu, University of Missouri–Kansas City, United States
Olga Kopach, University College London, United Kingdom
Copyright © 2023 Vukolova, Yen, Khmyz, Sobolevsky and Yelshanskaya. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maria V. Yelshanskaya, my2332@cumc.columbia.edu